Table 1 Baseline Characteristics
Characteristic | Overall (N = 75) | Infliximab + CS (N = 36) | CS Alone (N = 39) | P Value |
|---|---|---|---|---|
Median Age (Interquartile Range) |  | 63 years (50–71 years) | 61 years (52–72 years) | 0.633 |
Sex, No. (%) | ||||
 Male | 50 (66.7) | 29 (80.6) | 21 (53.8) | 0.016 |
 Female | 25 (33.3) | 7 (19.4) | 18 (46.2) | 0.016 |
Cancer Type, No. (%) | ||||
 Melanoma | 53 (70.7) | 29 (80.6) | 24 (61.5) | 0.167 |
 Genitourinarya | 15 (20.0) | 7 (19.4) | 8 (20.5) |  |
 Head and Neck Cancer | 1 (1.3) | 0 | 1 (2.6) |  |
 Leukemia | 1 (1.3) | 0 | 1 (2.6) |  |
 Lung Cancer | 2 (2.7) | 0 | 2 (5.1) |  |
 Otherb | 3 (4.0) | 0 | 3 (7.7) |  |
Immunotherapy Type, No. (%) | ||||
 Ipilimumab | 45 (60.0) | 21 (58.3) | 24 (61.5) | 0.834 |
 Ipilimumab + Nivolumab | 12 (16.0) | 6 (16.7) | 6 (15.4) |  |
 Nivolumab | 4 (5.3) | 1 (2.8) | 3 (7.7) |  |
 Pembrolizumab | 13 (17.3) | 7 (19.4) | 6 (15.4) |  |
 Tremelimumab | 1 (1.3) | 1 (2.8) | 0 |  |
Symptoms at Onset, No. (%) | ||||
 Diarrhea | 73 (97.3) | 36 (100) | 37 (94.9) | 0.494 |
 Nausea | 21 (28.0) | 8 (22.2) | 13 (33.3) | 0.315 |
 Vomiting | 11 (14.7) | 3 (8.3) | 8 (20.5) | 0.195 |
 Abdominal Cramps | 32 (42.7) | 13 (36.1) | 19 (48.7) | 0.351 |
 Blood in Stool | 22 (29.3) | 14 (38.9) | 8 (20.5) | 0.127 |
 Mucus in Stool | 2 (2.7) | 0 | 2 (5.1) | 0.494 |
 Elevated WBC Counts | 3 (4.0) | 1 (2.8) | 2 (5.1) | 1 |
Pathology, No. (%) | ||||
 Positive | 37 (49.3) | 20 (55.6) | 17 (43.6) | 0.534 |
 Negative | 6 (8.0) | 2 (5.6) | 4 (10.3) |  |
 Not Tested | 32 (42.7) | 14 (38.9) | 18 (46.2) |  |